Effects of inducing physiological hyperglucagonemia on metabolic responses to exercise.
The purpose of the present study was to assess the effects of exogenously increasing the circulating levels of glucagon on the metabolic responses to exercise in rats. A total of six groups of rats were infused (iv) either with glucagon (20 or 50 ng x kg(-1) x min(-1)) or saline (0.9% NaCl), either in the resting state or during a bout of running exercise (45 min, 26 m x min(-1), 0% grade). Blood samples were taken at the end of the 45-min experiment. Animals infused with glucagon at 50 ng x kg(-1) x min(-1) showed significantly (P<0.01) higher mean plasma glucagon concentrations than animals infused with saline or glucagon at 20 ng x kg(-1) x min(-1). In addition, exercise resulted in significantly (P<0.05) higher mean plasma glucagon concentrations, compared to rest, in all groups. In spite of these differences in glucagon concentrations, there were no significant (P>0.05) effects of exercise and glucagon infusion on mean hepatic glycogen, plasma glucose, insulin, C-peptide, beta-hydroxybutyrate, or catecholamine concentrations. Although exercise resulted in a significant (P<0.01) increase in plasma glycerol and free fatty acid concentrations and a significant (P<0.05) decrease in glycogen in the soleus muscle, these responses were not affected by the glucagon infusion. These results suggest that the liver is non-responsive to physiological hyperglucagonemia in a short-term (45 min) exercise situation.
Bélanger
Patrice
P
Département de kinésiologie, Université de Montréal, C.P. 6128 succ. Centre-ville, H3C 3J7 Montréal, Québec, Canada.
Fillion
Yovan
Y
Couturier
Karine
K
Gauthier
Marie-Soleil
MS
Lavoie
Jean-Marc
JM
D020155:3-Hydroxybutyric Acid / Q000097:blood / Q000378:metabolism; D000818:Animals; D000842:Ankle / Q000503:physiopathology; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D002096:C-Peptide / Q000032:analysis / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood / Q000378:metabolism; D005934:Glucagon / Q000008:administration & dosage* / Q000097:blood*; D005990:Glycerol / Q000097:blood / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006943:Hyperglycemia / Q000097:blood* / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood / Q000378:metabolism; D008112:Liver Glycogen / Q000097:blood / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D009638:Norepinephrine / Q000097:blood / Q000378:metabolism; D010805:Physical Conditioning, Animal; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values
D001786:Blood Glucose; D002096:C-Peptide; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D008112:Liver Glycogen; D006003:Glycogen; D005934:Glucagon; D005990:Glycerol; D020155:3-Hydroxybutyric Acid; D009638:Norepinephrine; D004837:Epinephrine